Announced the fourth positive data and safety monitoring board (DSMB) review for the Phase 3 EFZO-FIT™ study. The independent ...

Tyr Pharma Inc (ATYR) reports robust financial health and significant progress in its pivotal phase three study for pulmonary ...

Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...

Splenic abnormalities usually present as a focal lesion(s) or diffuse splenomegaly outside the context of trauma. Most ...

SAN DIEGO - aTyr Pharma, Inc. (NASDAQ: ATYR) reported a narrower-than-expected fourth quarter loss on Wednesday, but shares fell 4.8% in after-hours trading as investors focused on the company’s cash ...

Rare diseases - a medical condition so obscure that even your doctor has to Google. Despite their name, these diseases ...

Reports collaboration and license revenue related to the Kyorin Agreement was $200K for the year ended 2024, which consisted of drug product ...

The FDA approved a prefilled syringe format for Ani's purified Cortrophin Gel that should ease administration for MS patients ...

Kidney stones are solid accumulations that tend to form in the kidneys but can occur throughout the urinary system. Obstruction, pain and secondary infection are the most common symptoms with kidney ...